The Journal of Pediatrics
Volume 147, Issue 4 , Pages 521-527 , October 2005

Corticosteroids Versus Intravenous Immune Globulin for the Treatment of Acute Immune Thrombocytopenic Purpura in Children: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Received 14 September 2004 ,Revised 1 March 2005 ,Accepted 14 April 2005.

References 

  1. Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med. 2002;346:995–1008
  2. Kuhne T, Elinder G, Blanchette VS, Garvey B. Current management issues of childhood and adult immune thrombocytopenic purpura (ITP). Acta Paediatr. 1998;424(Suppl):75–81
  3. Woerner SJ, Abildgaard CF, French BN. Intracranial hemorrhage in children with idiopathic thrombocytopenic purpura. Pediatrics. 1981;67:453–460
  4. Medeiros D, Buchanan GR. Major hemorrhage in children with idiopathic thrombocytopenic purpura: immediate response to therapy and long-term outcome. J Pediatr. 1998;133:334–339
  5. Lilleyman JS. Intracranial hemorrhage in idiopathic thrombocytopenic purpura. Arch Dis Child. 1994;71:251–253
  6. Vesely SK, Buchanan GR, Adix L, George JN, Cohen AR, Blanchette VS, et al. Self-reported initial management of childhood idopathic thrombocytopenic purpura: results of a survey of members of the American Society of Pediatric Hematology/Oncology 2001. J Pediatr Hematol Oncol. 2003;25:130–133
  7. De Mattia D, Del Principe D, Del Vecchio GC, Jankovic M, Arrighini A, Giordano P, et al. Acute childhood idiopathic thrombocytopenic purpura: AIEOP consensus guidelines for diagnosis and treatment. Associazione Italiana di Ematologia e Oncologia Pediatrica. Haematologica. 2000;85:420–424
  8. George JN, Woolf SH, Raskob GE, Wasser JS, Aledort LM, Ballem PJ, et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood. 1996;88:3–40
  9. Eden OB, Lilleyman JS. Guidelines for management of idiopathic thrombocytopenic purpura. The British Paediatric Haematology Group. Arch Dis Child. 1992;67:1056–1058
  10. Buchanan GR, de Alarcon PA, Feig SA, Gilchrist GS, Lukens JN, Moertel CL, et al. Acute idiopathic thrombocytopenic purpura: management in childhood. Blood. 1997;89:1464–1465
  11. Landis J, Koch G. The measurement of observer agreement for categorical data. Biometrics. 1977;33:159–174
  12. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJM, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials. 1996;17:1–12
  13. Juniper EF, Guyatt GH, Jaeschke R. How to develop and validate a new health-related quality of life instrument. In:  Spilker B editors. Quality of Life and Pharmacoeconomics in Clinical Trials. 2nd ed.. Philadelphia, PA: Lippincott-Raven Publishers; 1996;p. 49–56
  14. Laupacis A, Sackett DL, Roberts RS. An assessment of clinically useful measures of the consequences of treatment. N Engl J Med. 1988;318:1728–1733
  15. Albayrak D, Islek I, Kalayci AG, Gurses N. Acute immune thrombocytopenic purpura: a comparative study of very high oral doses of methylprednisolone and intravenously administered immune globulin. J Pediatr. 1994;125:1004–1007
  16. Ancona KG, Parker RI, Atlas MP, Prakash D. Randomized trial of high-dose methylprednisolone versus intravenous immunoglobulin for the treatment of acute idiopathic thrombocytopenic purpura in children. J Pediatr Hematol Oncol. 2002;24:540–544
  17. Blanchette V, Imbach P, Andrew M, Adams M, McMillan J, Wang E, et al. Randomised trial of intravenous immunoglobulin G, intravenous anti-D, and oral prednisone in childhood acute immune thrombocytopenic purpura. Lancet. 1994;344:703–707
  18. Blanchette VS, Luke B, Andrew M, Sommerville-Nielsen S, Barnard D, De Veber B, et al. A prospective, randomized trial of high-dose intravenous immune globulin G therapy, oral prednisone therapy, and no therapy in childhood acute immune thrombocytopenic purpura. J Pediatr. 1993;123:989–995
  19. Duru F, Fisgin T, Yarali N, Kara A. Clinical course of children with immune thrombocytopenic purpura treated with intravenous immunoglobulin G or megadose methylprednisolone or observed without therapy. Pediatr Hematol Oncol. 2002;19:219–225
  20. Imbach P, Wagner HP, Berchtold W, Gaedicke G, Hirt A, Joller P, et al. Intravenous immunoglobulin versus oral corticosteroids in acute immune thrombocytopenic purpura in childhood. Lancet. 1985;2:464–468
  21. Khalifa AS, Tolba KA, el-Alfy MS, Gadallah M, Ibrahim FH. Idiopathic thrombocytopenic purpura in Egyptian children. Acta Haematol. 1993;90:125–129
  22. Ozsoylu S, Sayli TR, Ozturk G. Oral megadose methylprednisolone versus intravenous immunoglobulin for acute childhood idiopathic thrombocytopenic purpura. Pediatr Hematol Oncol. 1993;10:317–321
  23. Fujisawa K, Iyori H, Ohkawa H, Konishi S, Bessho F, Shirahata A, et al. A prospective, randomized trial of conventional, dose-accelerated corticosteroids and intravenous immunoglobulin in children with newly diagnosed idiopathic thrombocytopenic purpura. Int J Hematol. 2000;72:376–383
  24. Erduran E, Aslan Y, Gedik Y, Orhan F. A randomized and comparative study of intravenous immunoglobulin and mega dose methylprednisolone treatments in children with acute idiopathic thrombocytopenic purpura. Turk J Pediatr. 2003;45:295–300
  25. Imbach P, Akatsuka J, Blanchette V, Burek-Kozlowska A, Bussel J, Gaedicke G, et al. Immunothrombocytopenic purpura as a model for pathogenesis and treatment of autoimmunity. Eur J Pediatr. 1995;154(Suppl 3):S60–S64
  26. Calpin C, Dick P, Poon A, Feldman W. Is bone marrow aspiration needed in acute childhood idiopathic thrombocytopenic purpura to rule out leukemia?. Arch Pediatr Adolesc Med. 1998;152:345–347
  27. Tarantino MD. Acute immune (idiopathic) thrombocytopenic purpura in childhood. Blood Rev. 2002;16:19–21
  28. Thornton A, Lee P. Publication bias in meta-analysis: its causes and consequences. J Clin Epidemiol. 2000;53:207–216
  29. Buchanan GR, Holtkamp CA. Prednisone therapy for children with newly diagnosed idiopathic thrombocytopenic purpura: a randomized clinical trial. Am J Pediatr Hematol Oncol. 1984;6:355–361
  30. Kitchens CS. Amelioration of endothelial abnormalities by prednisone in experimental thrombocytopenia in the rabbit. J Clin Invest. 1977;60:1129–1134
  31. Sacks HS, Berrier J, Reitman D, Ancona-Berk VA, Chalmers TC. Meta-analyses of randomized controlled trials. N Engl J Med. 1987;316:450–455

 Dr Beck is supported through a studentship, fully or in part, by the Ontario Student Opportunity Trust Fund – Hospital for Sick Children Foundation Student Scholarship Program, and by a Canadian Institute for Health Research Fellowship.The Paediatric Outcomes Research Team (PORT) is supported by a grant from the Hospital for Sick Children.

PII: S0022-3476(05)00342-2

doi: 10.1016/j.jpeds.2005.04.032

The Journal of Pediatrics
Volume 147, Issue 4 , Pages 521-527 , October 2005

Article Tools

* Image Usage & Resolution